Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages 17-26

  Proudnikov, Dmitri ^a   Randesi, Matthew ^a   Levran, Orna ^a   Yuferov, Vadim ^a   Crystal, Howard ^b   Ho, Ann ^a   Ott, Jurg ^a,c   Kreek, Mary J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Downstate Health Sciences University   (United States)

^c INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

CD4 count; OPRK1; PDYN; polymorphism; SNP; viral load; WIHS

Indexed keywords

KAPPA OPIATE RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; EUROPEAN AMERICAN; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CXCR4; RECEPTORS, OPIOID, KAPPA; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84876295705     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318285cd0c     Document Type: Article

References (50)

1. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol. 2003;24:116-121.
2. Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology. 2003;309: 99-107.
3. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786-793.
4. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277: 959-965.
5. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-411.
6. Keet IP, Tang J, Klein MR, et al. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis. 1999;180:299-309.
7. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317: 944-947.
8. Pelak K, Goldstein DB, Walley NM, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis. 2010;201:1141-1149.
9. Novick DM, Kreek MJ, Des Jarlais DC, et al. Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: therapeutic, historical, and ethical aspects. NIDA Res Monogr. 1986;67:318-320.
10. Novick DM, Trigg HL, Des Jarlais DC, et al. Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol. 1989;29:181-185.
11. Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261:1008-1012.
12. Kreek MJ, Des Jarlais DC, Trepo CL, et al. Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. J Infect Dis. 1990;162:538-541.
13. Matsunaga M, Isowa T, Murakami H, et al. Association of polymorphism in the human mu-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. Brain Behav Immun. 2009;23: 931-935.
14. Grimm MC, Ben-Baruch A, Taub DD, et al. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterolo-gous desensitization. J Exp Med. 1998;188:317-325.
15. Rogers TJ, Steele AD, Howard OM, et al. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann N Y Acad Sci. 2000;917:19-28.
16. Szabo I, Chen XH, Xin L, et al. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci U S A. 2002;99:10276-10281.
17. Zhang N, Hodge D, Rogers TJ, et al. Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem. 2003;278:12729-12736.
18. Finley MJ, Chen X, Bardi G, et al. Bi-directional heterologous desensi-tization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J Neuroimmunol. 2008;197:114-123.
19. Zhang N, Oppenheim JJ. Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol. 2005;78: 1210-1214.
20. Song C, Rahim RT, Davey PC, et al. Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5. J Biol Chem. 2011;286:20354-20365.
21. Bessler H, Sztein MB, Serrate SA. Beta-endorphin modulation of IL-1-induced IL-2 production. Immunopharmacology. 1990;19:5-14.
22. Lokensgard JR, Gekker G, Peterson PK. k-Opioid receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4+ lymphocytes. Biochem Pharmacol. 2002; 63:1037-1041.
23. Peterson PK, Gekker G, Lokensgard JR, et al. Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes. Biochem Pharmacol. 2001;61:1145-1151.
24. Gekker G, Hu S, Wentland MP, et al. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther. 2004;309:600-606.
25. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22:1355-1363.
26. Feldman DN, Feldman JG, Greenblatt R, et al. CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev. 2009;21:81-93.
27. Crystal HA, Hamon S, Randesi M, et al. A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict Biol. 2012;17:181-191.
28. Kapadia F, Cook JA, Cohen MH, et al. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction. 2005;100:990-1002.
29. Proudnikov D, Randesi M, Levran O, et al. Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. J Infect Dis. 2012;205:1745-1756.
30. Proudnikov D, Kroslak T, Sipe JC, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J. 2010;10:232-242.
31. Williams TJ, LaForge KS, Gordon D, et al. Dynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol. 2007; 12:496-502.
32. Dahl JP, Weller AE, Kampman KM, et al. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:106-108.
33. Harrigan R. Measuring viral load in the clinical setting. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(suppl 1):S34-S40.
34. Schooley RT, Ramirez-Ronda C, Lange JM, et al. Virologic and immuno-logic benefits of initial combination therapy with zidovudine and zalcita-bine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis. 1996;173:1354-1366.
35. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
36. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry. 2006;11:1016-1024.
37. Taqi MM, Bazov I, Watanabe H, et al. Prodynorphin promoter SNP associated with alcohol dependence forms noncanonical AP-1 binding site that may influence gene expression in human brain. Brain Res. 2011; 1385:18-25.
38. Clarke TK, Krause K, Li T, et al. An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population. Addict Biol. 2009;14:366-370.
39. Kölsch H, Wagner M, Bilkei-Gorzó A, et al. Gene polymorphisms in prodynorphin (PDYN) are associated with episodic memory in the elderly. J Neural Transm. 2009;116:897-903.
40. Zimprich A, Kraus J, Wöltje M, et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neu-rochem. 2000;74:472-477.
41. Rouault M, Nielsen DA, Ho A, et al. Cell-specific effects of variants of the 68-base pair tandem repeat on prodynorphin gene promoter activity. Addict Biol. 2011;16:334-346.
42. Babbitt CC, Silverman JS, Haygood R, et al. Multiple functional variants in cis modulate PDYN expression. Mol Biol Evol. 2010;27:465-479.
43. Wei SG, Zhu YS, Lai JH, et al. Association between heroin dependence and prodynorphin gene polymorphisms. Brain Res Bull. 2011;85: 238-242.
44. Kapadia F, Vlahov D, Donahoe RM, et al. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis. 2005;41:1027-1034.
45. Zhang H, Kranzler HR, Yang BZ, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry. 2008;13:531-543.
46. Chartoff E, Sawyer A, Rachlin A, et al. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012;62:167-176.
47. Knoll AT, Muschamp JW, Sillivan SE, et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry. 2011;70:425-433.
48. Rogers G, Curry M, Oddy J, et al. Depressive disorders and unprotected casual anal sex among Australian homosexually active men in primary care. HIV Med. 2003;4:271-275.
49. Gerra G, Leonardi C, Cortese E, et al. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:771-775.
50. Yuferov V, Fussell D, LaForge KS, et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of hap-lotypes with opiate addiction. Pharmacogenetics. 2004;14:793-804.